EVD-Associated Uveitis

How it works

Risks & contraindications

Comparisons

Evidence quality

Other

Highlighted claims

• Uveitis is the most common ocular complication of Ebola virus disease. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
• The PREVAIL Study in Liberia found higher uveitis prevalence in EVD survivors than in close-contact controls. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
• Infectious EBOV was detected in aqueous humour after acute viremia had cleared in a convalescent survivor with severe panuveitis. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
• The case definition for EVD-associated uveitis requires current or prior uveitis or sequelae with symptoms or vision loss during or after EBOV infection and not attributable to other causes. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
• Across cohort studies, uveitis prevalence in EVD survivors ranged from 13% to 34%, compared with about 1% in controls. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation
• The article frames ocular immune privilege as a setting where EBOV can persist and drive vision-threatening inflammation after acute infection. — Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation